Am J Transplant, Volume 22, Suppl 3 Archives - Page 166 of 190 - ATC Abstracts

2022 American Transplant Congress
Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Solid Organ Transplant
H. Sweiss¹, D. Zeilmann¹, J. Escamilla², R. Hall¹, S. Bhayana¹, R. Patel¹, C. Long²
¹University Health - University Hospital, San Antonio, TX, ²College of Pharmacy, University of Incarnate Word, San Antonio, TX
*Purpose: To evaluate the safety and efficacy of glucagon-like peptide-1 receptor agonists (GLP1-RA) in solid organ transplant (SOT).*Methods: This retrospective review included adult kidney, liver,…
2022 American Transplant Congress
The Liver Regenerative Effect of Substance P After Major Hepatectomy in Rat Models
H. Ahn¹, H. Ko²
¹Surgery, Kyung Hee University, Seoul, Korea, Republic of, ²Kyung Hee University Hospital, Seoul, Korea, Republic of
*Purpose: The hepatic damages are inevitable under liver surgery. Therefore, post-hepatectomy liver failure remains one of the most dangerous and lifethreatening complications of hepatectomy. The…
2022 American Transplant Congress
Infections Requiring Hospitalization After Simultaneous Pancreas-Kidney Transplantation Compared to Kidney Transplantation Alone
J. Grasberger¹, F. Ortiz², A. Ekstrand², V. Sallinen¹, M. Lempinen¹, I. Helanterä¹
¹Transplantation and Liver Surgery, Helsinki University Hospital, Helsinki, Finland, ²Nephrology, Helsinki University Hospital, Helsinki, Finland
*Purpose: Although infections related to surgical complications are more common after simultaneous pancreas-kidney transplantation (SPK) compared to kidney transplantation alone (KTA), the burden of infections…
2022 American Transplant Congress
Galectin-3 is Predictive of 30-Day Acute Rejection Following Liver Transplantation
D. Yoeli, T. Ferrell, I. Rodriguez, N. Limon De La Rosa, N. Nakra, Z. Wang, E. Cervantes-Alvarez, R. Choudhury, M. Adams, T. Nydam, E. Pomfret, C. Huang, H. Moore, N. Navarro Alvarez
University of Colorado Anschutz Medical, Aurora, CO
*Purpose: Galectin-3 (Gal3) is a beta-galactoside binding lectin that plays a key role in inflammation and immune response. Studies on Gal3 in liver transplantation are…
2022 American Transplant Congress
Findings from Pharmacist-Performed Medication Adherence Assessments in Living Donor Kidney Transplant Candidates and Missed Medication Rates Early After Transplant
L. Nguyen¹, R. Samudralwar², A. Forte², G. Malat², C. Christopher¹, J. Rivera¹, T. Ilori¹, X. Liu¹, J. Trofe-Clark²
¹Pharmacy, Hosp of Univ of Pennsylvania, Philadelphia, PA, ²Penn Transplant Institute and Pharmacy Dept, Hosp of Univ of Pennsylvania, Philadelphia, PA
*Purpose: Evaluation and monitoring for medication non-adherence (NA) is necessary pre- and post-kidney transplant (KTx) to optimize outcomes. This study aims to describe findings post-implementation…
2022 American Transplant Congress
Successful Implementation of a Rural Appalachian Kidney Transplant Program; One Year Outcomes
F. Afridi¹, B. Gillis¹, R. Lopez¹, D. Kannabhiran¹, V. Chaudhary¹, M. Thornberg¹, R. Zomak¹, K. Meyer¹, C. Newman¹, L. Biondi²
¹Department of Surgery, West Virginia University, Morgantown, WV, ²Department of Surgery, West Virginia University, Morgantown, WV, WV
*Purpose: Kidney transplantation has become the optimal treatment for end stage renal disease (ESRD), allowing dialysis free survival. Despite widespread availability of transplant programs; rural…
2022 American Transplant Congress
Impact of Donor Type, Cold Ischemia Time, and Induction Type on Baseline Donor-Derived Cell-Free DNA in Kidney Transplant Recipients
K. K. Sureshkumar¹, A. Grazier², B. Chopra¹
¹Nephrology, Medicine Institute, Allegheny General Hospital, Pittsburgh, PA, ²Abdominal Transplantation, Allegheny General Hospital, Pittsburgh, PA
*Purpose: Donor derived cell free DNA (dd-cfDNA) is a biomarker useful in predicting acute rejection in kidney allografts. Baseline dd-cfDNA levels are
2022 American Transplant Congress
Six-Month Antibody Kinetics and Durability After Three Doses of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients
A. Abedon¹, J. Alejo¹, T. Chiang¹, J. Mitchell¹, J. Kim¹, L. Thomas¹, R. Avery¹, A. Tobian¹, A. Massie¹, M. Levan¹, D. Warren¹, J. Garonzik-Wang², D. Segev¹, W. Werbel¹
¹Johns Hopkins, Baltimore, MD, ²University of Wisconsin, Madison, WI
*Purpose: Some solid-organ transplant recipients (SOTRs) with low or negative antibody levels after a 2-dose mRNA vaccine series against SARS-CoV-2 experience boosting after a third…
2022 American Transplant Congress
Re-Infection with SARS-CoV-2 in Solid-Organ Transplant Recipients: Incidence Density and Convalescent Immunity Prior to Re-Infection
S. Morris¹, S. Anjan¹, S. Pallikkuth², P. Frattaroli³, S. Courel⁴, A. Fernandez⁵, A. Natori⁶, L. Abbo⁷, S. Pahwa², G. Guerra⁸, Y. Natori¹
¹Division of Infectious Disease, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, ²Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL, ³Medicine, Jackson Memorial Hospital, Miami, FL, ⁴University of Miami Miller School of Medicine, Miami, FL, ⁵Infectious Disease Associates of Tampa Bay, Tampa Bay, FL, ⁶Division of Oncology, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, ⁷Division of Infectious Disease, Department of Medicine, University Of Miami Miller School of Medicine, Miami, FL, ⁸Division of Nephrology, Department of Medicine, University of Miami Jackson Memorial Hospital, Miami, FL
*Purpose: The purpose of this study was to study our cohort of adult solid organ transplant recipients who had been infected with SARS-CoV-2 to describe…
2022 American Transplant Congress
The Role Of Gut Microbiome In Optimum Dose Selection Of Tacrolimus For Kidney Transplant Recipients
M. Nayebpour¹, N. Koizumi¹, J. Melancon²
¹George Mason University, Arlington, VA, ²George Washington University Hospital, Washington, DC
*Purpose: This study aims to validate and apply a personalized optimal dose selection model for Tacrolimus (Tac) for kidney transplant recipients at the George Washington…